Nursing hbrp Domain
Published April 27, 2026 | Version v1
Journal article Open

An Essential Parameters of Fosinopril Include Objectives, Indications, Mechanism of Action, Administration, Adverse Effects, Contra - Indications, Toxicity and Health Care Team Out Comes

Authors/Creators

Description

Angiotensin-converting enzyme (ACE) inhibitors, which have been used to treat cardiovascular diseases for almost thirty years, are related to fosinopril. Both heart failure and hypertension can now be treated with fosinopril, according to the US Food and Drug Administration (FDA). As a competitive inhibitor of ACE, fosinopril prevents angiotensin I from becoming an effective vasoconstrictor, angiotensin II. The following additional ACE inhibitors are authorized in the US: trandolapril, captopril, enalapril, lisinopril, benazepril, quinapril, ramipril, moexipril, and fosinopril.

HIV-associated nephropathy, diabetic nephropathy, and acute myocardial infarction are the conditions for which fosinopril is used off-label. The drug's hydrophilicity, resistance to hepatic breakdown, and extended half-life set it apart from enalapril and captopril. This exercise highlights the role of the interprofessional healthcare team in managing hypertension with fosinopril by providing information on the drug's mechanism of action, pharmacology, adverse event profiles, eligible patient categories, and monitoring.

Files

An Essential Parameters of Fosinopril -HBRP Publication.pdf

Files (574.1 kB)

Additional details

References

  • 1. National Institute of Diabetes and Digestive and Kidney Diseases. (2018, February 11). Angiotensin-converting enzyme inhibitors. In LiverTox: Clinical and research information on drug-induced liver injury [Internet]. National Institutes of Health. https://www.ncbi.nlm.nih.gov/books/NBK547852/
  • 2. Elliott, W. J. (2007). Systemic hypertension. Current Problems in Cardiology, 32(4), 201–259. https://doi.org/10.1016/j.cpcardiol.2007.01.001
  • 3. Shettigar, U., Hare, T., Gelperin, K., Ilgenfritz, J. P., Deitchman, D., & Blumenthal, M. (1999). Effects of fosinopril on exercise tolerance, symptoms, and clinical outcomes in patients with decompensated heart failure. Congestive Heart Failure, 5(1), 27–34.
  • 4. Erhardt, L., MacLean, A., Ilgenfritz, J., Gelperin, K., & Blumenthal, M. (1995). Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure: Fosinopril Efficacy/Safety Trial (FEST). European Heart Journal, 16(12), 1892–1899.
  • 5. Borghi, C., Marino, P., Zardini, P., Magnani, B., Collatina, S., & Ambrosioni, E. (1998). Short- and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: Results from the FAMIS study. American Heart Journal, 136(2), 213–225.
  • 6. Huang, Y. H., Wang, H. T., Zhu, Q. Z., Zhang, H., Shen, W., & Wang, Y. (2003). [Combination therapy with losartan and fosinopril for early diabetic nephropathy]. Di Yi Jun Yi Da Xue Xue Bao, 23(9), 963–965.
  • 7. Wei, A., Burns, G. C., Williams, B. A., Mohammed, N. B., Visintainer, P., & Sivak, S. L. (2003). Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney International, 64(4), 1462–1471. https://doi.org/10.1046/j.1523-1755.2003.00257.x
  • 8. Yoshiyama, M., Nakamura, Y., Omura, T., Izumi, Y., Matsumoto, R., Oda, S., Takeuchi, K., Kim, S., Iwao, H., & Yoshikawa, J. (2005). Angiotensin converting enzyme inhibitor prevents left ventricular remodeling after myocardial infarction in angiotensin II type 1 receptor knockout mice. Heart, 91(8), 1080–1085. https://doi.org/10.1136/hrt.2004.038810
  • 9. Düsing, R. (2016). Pharmacological interventions into the renin–angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: Effects beyond blood pressure lowering. Therapeutic Advances in Cardiovascular Disease, 10(3), 151–161. https://doi.org/10.1177/1753944716633224
  • 10. Song, J. C., & White, C. M. (2002). Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin-converting enzyme inhibitors: An update. Clinical Pharmacokinetics, 41(3), 207–224. https://doi.org/10.2165/00003088-200241030-00003